FDAnews
www.fdanews.com/articles/192112-fda-gives-go-ahead-for-first-lyrica-generics

FDA Gives Go-Ahead for First Lyrica Generics

July 24, 2019

The FDA has approved multiple applications of Lyrica (pregabalin) generics, marking the first generic versions of Pfizer’s nerve pain treatment to be approved in the U.S.

The agency gave the go-ahead for nine generic versions of Lyrica, a drug used to treat conditions including seizures, fibromyalgia and neuropathic pain. The drug’s common side effects include dry mouth, dizziness, swelling, blurred vision, weight gain and abnormal thinking.

Lyrica raked in $4.6 billion in sales last year for the drug titan.

View today's stories